Funding for this research was provided by:
Deutsche Krebshilfe (MSNZ programm)
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (Z-3R/2)
Deutsche Forschungsgemeinschaft (GRK2157, 2157)
Received: 12 August 2020
Accepted: 12 January 2021
First Online: 22 February 2021
: K.H. and S.K. are employees of Bristol Myers Squibb. M.H. is listed as an inventor on patent applications and granted patents related to CAR T cell therapy and CAR T cell technologies; he has received speaker honoraria from Celgene/Bristol Myers Squibb, Janssen and Kite/Gilead. H.E. received research funding from Janssen, Bristol Myers Squibb/Celgene, Amgen, Novartis, Sanofi, GSK and Janssen and has received speaker honoraria from Bristol Myers Squibb/Celgene, Amgen, Novartis, Takeda, Sanofi and GSK. L.R. has received speaker honoraria from Bristol Myers Squibb/Celgene, Sanofi, GSK, Oncopeptides and Janssen. The remaining authors declare no competing interests.